US
CA
NZ
UK
AU
IND
Last update at 2025-05-05T13:57:11.125718Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
49 Public Companies to Present at the SNN Network Virtual Conference on August 3-6, 2020
Mon 03 Aug 20, 12:00 PM| Breakdown | 2023-12-31 | 2023-01-31 | 2022-12-31 | 2022-01-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2023-01-31 | 2022-12-31 | 2022-01-31 | 2021-12-31 |
| Income before tax | -28.96200M | -19.44500M | -19.44500M | -19.12700M | -19.12700M |
| Minority interest | - | - | - | - | - |
| Net income | -28.96200M | -21.08600M | -21.08600M | -21.51300M | -21.51300M |
| Selling general administrative | 21.14M | 13.07M | 13.07M | 8.67M | 8.67M |
| Selling and marketing expenses | 0.62M | - | - | - | - |
| Gross profit | 0.16M | -19.78200M | -19.78200M | -0.71500M | -0.71500M |
| Reconciled depreciation | - | 0.26M | 0.26M | 0.78M | 0.78M |
| Ebit | -31.91600M | -19.92300M | -19.44500M | -18.83800M | -19.06000M |
| Ebitda | -31.67800M | -17.54800M | -19.86900M | -13.96500M | -18.25500M |
| Depreciation and amortization | 0.24M | 2.38M | -0.42400M | 4.87M | 0.81M |
| Non operating income net other | - | - | - | - | - |
| Operating income | -31.91600M | -19.92300M | -19.92300M | -18.83800M | -18.83800M |
| Other operating expenses | 32.12M | 20.06M | 20.06M | 17.19M | 17.19M |
| Interest expense | - | 0.48M | 0.48M | 0.07M | 0.07M |
| Tax provision | - | - | - | - | - |
| Interest income | - | 1.05M | 0.63M | 0.27M | 0.00000M |
| Net interest income | - | 0.63M | 0.63M | -0.06700M | -0.06700M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | - | 1.64M | 1.64M | 2.39M | 2.39M |
| Total revenue | 0.20M | 0.14M | 0.14M | 0.14M | 0.14M |
| Total operating expenses | 32.08M | 20.06M | 20.06M | 16.34M | 16.34M |
| Cost of revenue | 0.04M | 19.92M | 19.92M | 0.85M | 0.85M |
| Total other income expense net | 2.95M | 0.48M | 0.48M | -0.28900M | -0.28900M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | - | -19.44500M | -19.44500M | -19.12700M | -19.12700M |
| Net income applicable to common shares | - | -19.44500M | - | -19.12700M | - |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2023-01-31 | 2022-12-31 | 2022-01-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2023-01-31 | 2022-12-31 | 2022-01-31 | 2021-12-31 |
| Total assets | 19.38M | 40.49M | 40.49M | 57.70M | 57.70M |
| Intangible assets | 2.31M | 1.94M | 1.94M | 1.97M | 1.97M |
| Earning assets | - | - | - | - | - |
| Other current assets | 0.60M | 0.46M | 0.46M | 0.30M | 0.30M |
| Total liab | 9.15M | 2.02M | 2.02M | 0.82M | 0.82M |
| Total stockholder equity | 10.23M | 38.47M | 38.47M | 56.88M | 56.88M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 1.76M | 0.81M | 0.81M | 0.44M | 0.44M |
| Common stock | 0.05M | 0.05M | 0.05M | 0.05M | 0.05M |
| Capital stock | - | 0.74M | 0.74M | 0.76M | 0.76M |
| Retained earnings | -409.50800M | -380.54600M | -380.54600M | -361.10100M | -361.10100M |
| Other liab | - | - | - | 0.04M | - |
| Good will | - | - | - | - | - |
| Other assets | 0.00000M | 1.20M | - | 1.32M | - |
| Cash | 5.44M | 27.05M | 27.05M | 32.09M | 32.09M |
| Cash and equivalents | - | 27.05M | - | 32.09M | - |
| Total current liabilities | 8.65M | 1.36M | 1.36M | 0.67M | 0.67M |
| Current deferred revenue | -0.22300M | - | - | - | - |
| Net debt | -4.72100M | -26.21600M | -26.21600M | -31.94400M | -31.94400M |
| Short term debt | 0.45M | 0.18M | 0.18M | 0.04M | 0.04M |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 0.72M | 0.84M | 0.84M | 0.15M | 0.15M |
| Other stockholder equity | 419.00M | 418.27M | 418.27M | 417.22M | 417.22M |
| Property plant equipment | - | 1.02M | - | 4.20M | - |
| Total current assets | 14.56M | 36.32M | 36.32M | 50.21M | 50.21M |
| Long term investments | - | - | - | 0.00000M | 0.00000M |
| Net tangible assets | - | - | - | 54.19M | - |
| Short term investments | 7.63M | 7.14M | 7.14M | 16.18M | 16.18M |
| Net receivables | 1.18M | 1.68M | 1.68M | 1.64M | 1.64M |
| Long term debt | - | - | - | - | - |
| Inventory | -0.30200M | - | - | - | - |
| Accounts payable | 6.44M | 0.38M | 0.38M | 0.20M | 0.20M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 0.00000M | - | - | - | - |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 1.69M | 1.20M | 1.20M | 1.32M | 1.32M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 4.83M | 4.17M | 4.17M | 7.49M | 7.49M |
| Capital lease obligations | - | 0.84M | 0.84M | 0.15M | 0.15M |
| Long term debt total | - | 0.00000M | - | 0.00000M | - |
| Breakdown | 2023-12-31 | 2023-01-31 | 2022-12-31 | 2022-01-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2023-01-31 | 2022-12-31 | 2022-01-31 | 2021-12-31 |
| Investments | - | 10.99M | 10.99M | -0.63100M | -0.63100M |
| Change to liabilities | - | - | - | -0.18500M | - |
| Total cashflows from investing activities | - | 10.99M | - | -0.63100M | - |
| Net borrowings | - | - | - | -4.85400M | - |
| Total cash from financing activities | 0.48M | 0.08M | 0.08M | 8.19M | 8.19M |
| Change to operating activities | - | - | - | 1.05M | - |
| Net income | -28.96200M | -19.44500M | -19.44500M | -19.12700M | -19.12700M |
| Change in cash | -21.61400M | -5.04000M | -5.04000M | -6.40800M | -6.40800M |
| Begin period cash flow | 27.05M | 32.09M | 32.09M | 38.50M | 38.50M |
| End period cash flow | 5.44M | 27.05M | 27.05M | 32.09M | 32.09M |
| Total cash from operating activities | -21.26700M | -16.10800M | -16.10800M | -13.96500M | -13.96500M |
| Issuance of capital stock | - | 0.08M | 0.08M | 13.04M | 13.04M |
| Depreciation | 0.24M | 0.26M | 0.26M | 0.78M | 0.78M |
| Other cashflows from investing activities | - | 11.26M | - | 0.00200M | - |
| Dividends paid | - | - | - | - | - |
| Change to inventory | - | - | 0.04M | - | - |
| Change to account receivables | 0.49M | 0.00000M | -0.03500M | 0.03M | 0.03M |
| Sale purchase of stock | - | 0.08M | - | 13.04M | - |
| Other cashflows from financing activities | 0.48M | 10.99M | 10.99M | -0.63100M | 13.04M |
| Change to netincome | - | - | - | 3.44M | - |
| Capital expenditures | 0.58M | 0.27M | 0.27M | 0.63M | 0.63M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | 1.06M | 0.97M | 0.97M | 0.90M | 0.90M |
| Stock based compensation | 0.24M | 0.95M | 0.95M | 1.57M | 1.57M |
| Other non cash items | 0.31M | 0.96M | 0.96M | 4.24M | 4.24M |
| Free cash flow | -21.85200M | -16.37900M | -16.37900M | -14.59800M | -14.59800M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| AIM AIM ImmunoTech Inc |
- -% | - | - | - | 69.54 | 4.53 | 49.40 | 0.49 |
| NVO Novo Nordisk A/S |
-0.56 0.69% | 80.49 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
-0.41 0.51% | 80.59 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-1.29 0.28% | 458.77 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
2.82 0.54% | 524.66 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.
2117 SW Highway 484, Ocala, FL, United States, 34473
| Name | Title | Year Born |
|---|---|---|
| Mr. Thomas K. Equels Esq., J.D., M.S. | Exec. Vice Chairman, CEO & Pres | 1953 |
| Mr. Peter W. Rodino III, Esq., J.D. | COO, Exec. Director of Gov.al Relations, Gen. Counsel & Sec. | 1951 |
| Mr. Robert Dickey IV, M.B.A. | Chief Financial Officer | 1956 |
| Dr. David R. Strayer M.D. | Chief Scientific Officer & Medical Director | 1946 |
| Ann Marie E. Coverly | Director of Admin. & HR and Deputy Investor Relations Coordinator | NA |
| Dr. Carol A. Smith | Chief Manufacturing Officer & Deputy Chief Scientific Officer | 1951 |
| Jodie Pelz | Controller | NA |
| Dr. Ralph Christopher Cavalli Ph.D. | VP of QC & Manufacturing | 1958 |
| Mr. Thomas K. Equels Esq., J.D., M.S. | Executive Vice Chairman, CEO & President | 1953 |
| Mr. Robert Dickey IV, M.B.A. | Chief Financial Officer | 1955 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes. This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API. Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...